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Abstract 
Background: We evaluate prevalence of new abnormal glucose tolerance (AGT) in post MI 
survivors without known DM if guidelines are followed and compare the ability of admission 
(APG),fasting (FPG) and 2 hour post-load plasma glucose (2h-PG) to predict prognosis.   
 
Methods: 674 patients were followed up of 4 years for incidence of major adverse 
cardiovascular events (MACE) of cardiovascular death, non-fatal re-infarction or non-
haemorrhagic stroke. Ability of logistic regression models including APG, FPG and 2h-PG 
alone or in combination to predict MACE were compared. 
 
Results: 93-96% of impaired glucose tolerance and 64-75% of DM on OGTT would be 
missed with current guidelines. 134 MACEs recorded, higher in the upper quartiles of 2h-PG. 
The 2h-PG and FPG included individually into Cox proportional hazard regression models, 
predicted MACE. When included simultaneously, only 2h-PG predicted MACE (HR 1.12, CI 
1.04-1.20, p=0.0012), all cause mortality (HR 1.17, CI 1.05 - 1.30, p=0.0039), cardiovascular 
mortality (HR 1.17, CI 1.02 - 1.33, p=0.0205) and non-fatal MI (HR 1.10, CI 1.01 - 1.20, 
p=0.0291). Adding 2h-PG significantly improved ability of models including FPG (χ2  = 
16.01, df = 1, p = 0.0001) or FPG and APG (χ2  = 17.36, df = 1, p = 0.000) to predict MACE. 
Addition FPG or APG to models including 2h-PG did not improve its predictability.  Model 
including 2h-PG only with other covariates had the lowest Akaike’s information criteria and 
highest Akaike weights suggesting that this was the best in predicting events. Adding 2h-PG 
to models including FPG or APG with other co-variates yielded continuous net 
reclassification improvement of 0.22 (p = 0.026) and 0.27 (p = 0.005) and categorical net 
reclassification improvement of 0.09 (p = 0.032) and 0.12 (p = 0.014) respectively. Neither 
FPG nor APG improved net reclassification of model including 2h-PG. Adding 2h-PG to 
models including only FPG, only RPG and both yielded integrated discrimination 
improvement of 0.012 (p= 0.015), 0.022 (p = 0.001) and 0.013 (p = 0.014) respectively.  
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Conclusion: AGT is under-diagnosed on current guidelines. FPG and APG are not predictors 
of prognosis when considered with 2h-PG. 2h-PG is seemingly a better predictor of 
prognosis compared to APG and FPG. 
 
Keywords: diabetes, myocardial infarction, acute coronary syndrome, oral glucose tolerance, 
impaired glucose tolerance, prognosis, glycated haemoglobin, glycosylated haemoglobin,  
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Background 
Current guidelines [1,2] do not recommend routine use of oral glucose tolerance test (OGTT) 
to identify abnormal glucose tolerance (AGT) in patients without known diabetes mellitus 
(DM) admitted with acute coronary syndromes (ACS). These guidelines are not based on 
prognostic studies.[3-7].  It is reasonable to suggest that the most important measure of the 
glucometabolic state would be the one that determines long term prognosis after ACS.  
 
Elevated admission (APG), [8-13] fasting plasma glucose (FPG), [14-21] admission 
glycosylated haemoglobin (HbA1c)[22-26] and newly diagnosed AGT [27-31] after 
myocardial infarction (MI) and ACS in patients without known DM adversely affect prognosis. 
However, the ability of APG, FPG and 2 hours post-load plasma glucose (2h-PG) to predict 
post-ACS prognosis in same group of patients without known DM has not been evaluated. 
Studies exploring relationship between abnormal APG, FPG or 2h-PG and prognosis, have 
done so using dichotomous groupings e.g. those above and below a cut-off point [27] or 
conventional classifications of normal (NGT) or impaired glucose tolerance (IGT) and new 
DM (NDM)[28-35] rather than through a study of the predictability of these measurements as 
continuous variables. Furthermore, information on the independent effect of 2h-PG on 
prognosis is limited.[28,29,33]    
 
In the present study, we evaluate the effect of the current guidelines on the prevalence of 
new AGT in patients with ACS and compare the predictive value of APG, FPG and 2h-PG on 
prognosis after MI in patients without known DM. 
 
Methods 
As reported,[31] we retrospectively analysed standard dataset collected locally for the 
Myocardial Infarction National Audit Project (MINAP) on 768 consecutive post MI [36] 
survivors admitted between November 2005 and October 2008 without known DM who 
 5 
underwent pre-discharge OGTT. This study includes patients for whom APG, FPG and 2h-
PG were available. 
 
“Known DM” was diagnosed from history i.e. the patient had been informed of the diagnosis 
by a physician before the admission or was on anti-diabetic treatment. HbA1c was not used 
in diagnosing pre-hospital diabetes as it was not recommended in contemporary guidance. 
[37-39] FPG and OGTT were done on/after the third day of admission. We defined 
admission hyperglycaemia (AH) as APG ≥7.8 mmol/l [5] and DM as APG >11.1 mmol/l.[40] 
The patients were classified as normal glucose tolerance (NGT), impaired fasting glucose 
(IFG), IGT and NDM as follows: normal glucose tolerance (NGT): FPG <6·1 mmol/l and a 2-
h PG <7·8 mmol/l; imapired fasting glucose (IFG): FPG 6·1–6·9 mmol/l and 2-h PG <7·8 
mmol/l; IGT: FPG <7 mmol/l and 2-h PG 7·8–11 mmol/l. NDM:  FPG ≥7·0 and/or 2-h PG 
≥11·1 mmol/l. The patients were divided into quartiles of 2h-PG. The patients with IGT and 
NDM were advised lifestyle modification including diet, physical activity and referred to the 
diabetologists for appropriate out-patients management. 
 
All participants were followed up for a median of 48 months for outcomes. Completeness of 
follow up was ensured by manual review of hospital and general practice records. The first 
occurrence of an adverse event was obtained from hospital and general practice records 
and confirmed by the office of public health intelligence. The major adverse cardiovascular 
event (MACE) was defined as cardiovascular death, non-fatal re-infarction or non-
haemorrhagic stroke. Cardiovascular death was defined as death from MI, heart failure or 
sudden death. A non-fatal re-infarction was a non-fatal MI occurring later than 72 h after the 
index infarction. Stroke was defined as a neurological deficit persisting >24 hours as 
observed by a physician with radiological confirmation. As this study retrospectively 
analysed routinely collected anonymised data on standard clinical practice for MINAP, the 
East Yorkshire and North Lincolnshire Research Ethics Committee confirmed that formal 
patient consent and ethical approval was not required. [31] 
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Statistics 
Continuous variables are presented as mean±SD and median (interquartile range, IR) and 
categorical variables as counts and proportions (%). The baseline characteristics of quartiles 
were compared using one-way analysis of variance and Kruskal-Wallis test for parametric 
and non-parametric data respectively for continuous variables and chi-squared test for 
categorical variables. Correlations were assessed with Spearman’s rank correlation 
coefficient (ρ). Event-free survival curves were estimated by the Kaplan-Meier method 
compared using the Log-rank test. Cox proportional-hazards regression was used to analyse 
the effect of several variables on event free survival. Age, gender, smoking status, 
hypercholesterolemia, hypertension, history of previous MI, diagnosis at discharge, 
discharge prescription of aspirin, clopidogrel, beta-blockers, angiotensin-converting enzyme 
inhibitors and statins, revascularisation status, and glucometabolic status were “entered” into 
the model. Hazard ratios (HRs) and 95% confidence intervals (CIs) are reported. 
Multicollinearity was examined using variance inflation factor (VIF) (MedCalc Statistical 
Software version 17.0.4, Ostend, Belgium) and variables with VIF<4 were included in the 
same model.  
 
Nested models were compared using χ2 likelihood ratio tests to determine whether the 
logistic regression models including APG, FPG and 2h PG provided a significantly better fit 
than those with variables individually, in pairs and vice versa. Nested and non-nested 
models containing one of either APG, FPG, 2h-PG or a combination were compared using 
the corrected Akaike’s information criterion (AICc), δAICc, Akaike weights (wi) and evidence 
ratios to estimate of the probability that a given model is the best fitting model of those 
studied. [41,42] 
 
Logistic regression analysis of models including APG, FPG and 2h-PG, individually and in 
combination, along with the other above covariates was used to compute the predicted 
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probabilities of MACE. The incremental predictive value of adding 2h-PG to models with 
APG and FPG was analyzed from these predicted probabilities using several measures: 
categorical (cNRI) and category-free continuous net reclassification improvement (NRI>0) 
and integrated discrimination improvement (IDI). In the absence of clearly pre-defined 
clinical risk thresholds for the models, we opted not to use arbitrary cut-offs for risk. Instead, 
the predicted probabilities for the most restricted model were divided into quartiles to define 
the risk categories for calculating categorical NRI. The event (NRIe) and non-event NRI 
(NRIne) were defined as net percentage of persons with and without the event of interest 
correctly assigned a higher and lower predicted risk respectively. The overall NRI is the sum 
of NRIe and NRIne reported as a number. The IDI was defined as the mean difference in 
predicted risks between those with and without events.  
 
 
Results 
Of the 674 patients included, 70.3% had normal APG (Figure 1).  Of those without AH 35.0% 
had IGT and 15.2% had NDM. Of those with AH, 79.0% had normal FPG, of which 47.5% 
and 18.4% had IGT and NDM respectively. AGT would be missed in 52.0% patients with AH 
without OGTT. If AH was not considered, 89.3% had normal FPG. Of these, 38.6% and 
14.3% had IGT and NDM respectively. Thus IGT and NDM would be diagnosed only in 1.3% 
and 4.9% patients on following CG130[1] and 2.5% and 7.1% patients on following ESC 
Guidance[2] respectively. The clinical characteristics of patients in each 2h-PG quartiles are 
shown in Table 1. All the patients in the 1st quartile and 78.7% in the 2nd quartile had NGT; 
21.3% in the 2nd quartile. All patients in the 3rd quartile and 22.7% in the 4th quartile had 
IGT. The rest in the 4th quartile had NDM. FPG was <6.1 mmol/l in 83.3% patients with 2h-
PG ≥7.8 mmol/l 
 
MACE and non-fatal MIs were higher in the upper glucose quartiles (Table 2). Event-free 
survival significantly reduced with increasing quartiles of 2h-PG even below the conventional 
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threshold for DM (Figure 2). There was only a moderate correlation between FPG and 2h-
PG (ρ, 0.39, p<0.0001), FPG and RPG (ρ 0.33, p<0.0001) and RPG and 2h-PG (ρ 0.32, 
p<0.0001). The multicollinearity between these variables was low (VIF: FPG 1.56, 2h-PG 
1.50 and APG 1.32). Thus they were included into Cox proportional hazard regression 
models individually and in combinations. When APG, FPG or 2h-PG were included 
individually with other covariates (Table 3), 2h-PG independently predicted all, FPG 
predicted some but APG did not predict any outcomes. The risk of adverse events increased 
by 9-19% for each mmol/l rise in 2h-PG and by 18-44% for each increasing quartile of 2h-
PG. In a model including FPG, 2h-PG and APG, 2h-PG consistently remained an 
independent predictor of survival (Table 4) free of MACE (HR 1.12, CI 1.04-1.20, p=0.0012), 
all cause mortality (HR 1.17, CI 1.05 - 1.30, p=0.0039), cardiovascular mortality (HR 1.17, CI 
1.02 - 1.33, p=0.0205) and non-fatal MI (HR 1.10, CI 1.01 - 1.20, p=0.0291) but neither FPG 
nor APG predicted events.  
 
Nested models were compared using likelihood ratio tests to determine whether logistic 
regression models that included 2h-PG provided a significantly better fit than that limited to 
the APG, FPG or its combination (Table 5). This showed that addition of the 2h-PG 
significantly improved the ability of a model including FPG to predict MACE (χ2  = 16.01, df = 
1, p = 0.0001), all deaths (χ2  = 7.75, df = 1, p = 0.005), cardiovascular deaths (χ2  = 4.90, df 
= 1, p = 0.027) and myocardial infarction (χ2  = 8.64, df = 1, p = 0.003). Addition of 2h-PG to 
models including FPG and APG improved the ability of the later to predict MACE (χ2  = 
17.36, df = 1, p = 0.000), all deaths (χ2  = 7.85,, df = 1, p = 0.005), cardiovascular death (χ2  
= 6.04, df = 1, p = 0.014) and MI (χ2  = 8.57, df = 1, p = 0.003). However, addition of FPG or 
APG to a model including 2h-PG did not improve its predictability.   
 
The model including 2h-PG as the only measure of the glucometabolic state with other 
covariates had the lowest AICc and the highest wi  suggesting that these models were the 
best in predicting all events (Table 6). The δAICc suggests that addition of FPG or RPG to 
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these models worsen the AICc. Models with FPG or APG alone or in combination are 
inadequate. On comparing non-nested models (Table 7) containing FPG, APG and 2h-PG, 
the later consistently had the lowest AICc. It also has a 98% , 71%, 66% and 82% chance of 
being the “best” model among these for predicting MACE, all deaths, cardiovascular deaths 
and MI respectively. 
 
The addition of 2h-PG to a logistic regression models including FPG or RPG with other co-
variates to calculate risk of MACE at the end of follow up led to a continuous net 
reclassification improvement of 0.22 (p = 0.026) and 0.27 (p = 0.005) respectively.  Adding 
2h-PG to a model including FPG and RPG led to a NRI>0 of 0.19 (p = 0.046). Addition of 
either FPG or RPG to a model including 2h-PG did not significantly improve net 
reclassification. Similarly addition of 2h-PG to models including FPG or RPG led to a 
categorical net reclassification improvement of 0.09 (p = 0.032) and 0.12 (p = 0.014) 
respectively.  Addition of either FPG or RPG to a model including 2h-PG did not significantly 
improve net reclassification. Adding 2h-PG to models including only FPG, only RPG and 
both yielded IDI of 0.012 (p= 0.015), 0.022 (p = 0.001) and 0.013 (p = 0.014) respectively.  
 
Discussion 
Our study suggests that 1) AGT after an MI is under-diagnosed if current guidelines are 
followed, 2) FPG, but not APG, when considered alone independently predicts post-MI 
prognosis, 3) FPG ceases to be an independent predictor when included with 2h-PG in the 
same model and 4) 2h-PG may be a better independent predictor of prognosis compared to 
APG and FPG. 
 
The prevalence of AGT resembles Euro Heart Survey[43] suggesting a true estimate. AGT is 
underestimated without OGTT.[5,28,31,44,45] If CG130[1] is followed, 70% of our patients 
would not have further tests. This proportion would increase if higher threshold of APG was 
used for AH. As plasma glucose is overestimated early after MI,[30,46] it is likely that 
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number of patients with abnormal FPG would decrease if more patients were tested later 
thus reducing the number of patients undergoing OGTT even further. If ESC Guidance[2] is 
followed, 89% of our patients would not have OGTT. HbA1c is unlikely to be raised in all of 
these patients with normal FPG. Thus a large proportion of these patients with normal 
HbA1c and FPG would not be offered further testing. Thus AGT after an MI would be 
substantially under-diagnosed if current guidelines are followed. 
 
Current Guidelines are not based on prognostic studies.[3-7] This is the first study to assess 
the relative importance of APG, FPG and 2h-PG in determining post-MI prognosis in the 
same patients. Studies suggesting adverse post-MI prognosis in newly diagnosed AGT,[27-
31,33,34] have not shown 2h-PG to be independent predictor of event-free survival. 
Moreover, the cut-offs defining glucometabolic categories suggested by WHO and ADA for 
epidemiological purposes may be somewhat arbitrary soon after an MI. As increasing 
plasma glucose is likely to affect post-MI prognosis as a continuum, it was important to test 
the relative ability of these measurements as continuous variables in predicting outcomes. 
Increasing tertiles of FPG  even below conventional levels of abnormality independently 
affects prognosis.[15] The risk of events increase with each increasing quartiles of 2h-PG in 
our study. The 2h-PG independently affected outcomes even when included in the same 
model as the FPG and APG.  
 
Epidemiological studies suggest that 2h-PG is better than FPG alone at identifying increased 
prognostic risk.[45,47,48] The relative value of FPG, APG and 2h-PG in predicting post-MI 
prognosis in the same population of patients had not been tested. Tamita et al[28,33] 
showed that neither APG nor FPG independently predicted MACE; the effect of 2h-PG was 
not reported. FPG may be a better predictor of prognosis than APG.[14,15] Ravid et al[20] 
suggested FPG was more important in predicting the course of the MI, than the results of 
OGTT. In our study, adding 2h-PG to models including APG and/or FPG significantly 
improved their ability to predict prognosis. The models containing 2h-PG yielded best AIC 
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and demonstrated a very high probability of representing the best model. Adding 2h-PG to 
logistic regression models containing FPG significantly improved the net reclassification and 
the integrated discrimination of these models. Thus 2h-PG may be a more powerful predictor 
of event-free survival than FPG or APG. The increased macrovascular morbidity associated 
with higher 2h-PG rather than FPG seen here may be related to progression of 
atherosclerosis demonstrated with post-challenge rather than fasting hyperglycaemia.[49-53]  
 
Whether OGTT after MI reflects “true” glucometabolic state is debated. The pre-discharge 
glucometabolic category may[30,34,46] or may not[54,55] change with time. The infarct size 
and timing of OGTT may influence its ability to predict long term glucometabolic 
status.[30,46,54-56] The accuracy of pre-discharge OGTT in diagnosing NDM or IGT is 
pertinent for studies using OGTT to categorise patients to these groups.[27-31,33,34] As 
pre-discharge 2h-PG much below the conventional abnormal thresholds predicted risk of 
MACE irrespective of the categorisation of patients, the long term reproducibility of these 
categorisations may be less relevant when assessing prognostic risk. OGTT was done at 
least three days after the index event and 60% patients had NSTEMI. These two opposing 
influences may have limited the effect of stress dysglycaemia on our results.  
 
HbA1c was not measured as per guidance.[37-39] Prevalence of HbA1c ≥ 6.5% is 5-7% in 
similar populations.[6,7,23,24] Thus most of our patients with normal FPG and HbA1c would 
not qualify for OGTT.[1,2] Consequently, a large proportion of AGT would be missed. HbA1c 
has predicted post-MI prognosis in some [23,57-59] but not all studies.[24,60-63] The 2h-
PG, but not HbA1c, predicted prognosis in studies comparing the two [24,62] Kowalczyk et 
al suggest that the HbA1c may be useful in further risk stratifying patients diagnosed with 
new AGT but do not report the effect of HbA1c on prognosis of patients without AGT.[64] 
This suggests that usefulness of HbA1c in determining post-MI prognosis is seemingly 
unclear. HbA1c <6.5%, would leave many patients with undiagnosed AGT and unidentified 
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risk of future adverse events according to current guideline. HbA1c ≥6.5% may not predict 
risk. Under both conditions an OGTT may be useful to determine prognosis. 
 
This study has the limitations of an observational study using retrospective analysis of data 
collected from a single centre. Although national death register was not consulted directly, a 
linked general practice database was used. Information recorded incompletely could not be 
used in statistical models. Exclusion of small number of patients, albeit for valid reasons, and 
mainly Caucasian study population could affect the generalizability of the results. The effect 
of random glycaemic fluctuations or stress hyperglycaemia on the results can not be 
excluded. However, as pre-discharge 2h-PG predicted post-MI outcomes, the reproducibility 
of these measurements and its relation to long term glucometabolic status may be less 
relevant when assessing prognostic risk. 
 
Conclusion 
New AGT after an MI is under-diagnosed on following current guidelines. 2h-PG is likely to 
be a better predictor of long term prognosis than FPG or APG, Although FPG may on its own 
independently predict long term prognosis, it ceases to be an independent predictor when 
considered with 2h-PG. An appropriately timed OGTT may be useful to determine long term 
prognosis in post-MI patients without known diabetes. 
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List of abbreviations 
OGTT = oral glucose tolerance test 
AGT = abnormal glucose tolerance 
DM = diabetes mellitus 
ACS = acute coronary syndromes 
APG = admission plasma glucose  
FPG = fasting plasma glucose 
HbA1c = glycosylated haemoglobin 
MI = myocardial infarction  
2h-PG = 2 hours post-load plasma glucose 
NGT = normal glucose tolerance 
IGT = impaired glucose tolerance 
NDM = new DM 
MINAP = Myocardial Infarction National Audit Project 
AH = admission hyperglycaemia 
IFG = impaired fasting glucose 
MACE = major adverse cardiovascular event  
HR = Hazard ratios  
CI = confidence intervals 
VIF = variance inflation factor 
AIC = Akaike’s information criterion  
AICc = corrected Akaike’s information criterion  
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cNRI = categorical net reclassification improvement  
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NRIne = non-event net reclassification improvement  
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Table 1. Clinical characteristics of the study population categorised by quartiles of 2h post load 
glucose.  
 Q1,<6.6 
(n=165) 
Q2,6.6-8.1 
(n=160) 
 Q3,8.2-10.5 
(n=177) 
Q4,>10.5 
(n=172) 
p 
Age(years; median; IQR) 61(13) 64(17) 67(18) 69(20) 0.00 
Male n (%) 120(72.7) 109(68.1) 131(74.0) 122(70.9) 0.66 
Non-smoker n (%) 41(24.9) 48(30.0) 50(28.3) 57(33.1) 0.40 
Hypertension n (%) 43(26.1) 69(43.1) 73(41.2) 79(45.9) 0.00 
Hypercholesterolaemia n (%) 73(44.2) 86(53.8) 82(46.3) 79(45.9) 0.32 
Previous AMI n (%) 22(13.3) 27(16.9) 39(22.0) 36(20.9) 0.15 
Known IHD n (%) 36(21.8) 48(30.0) 55(31.1) 60(34.9) 0.06 
Diagnosis STEMI n (%) 67(40.6) 70(43.8) 82(46.3) 70(40.7) 0.66 
Discharge medications      
  Aspirin n (%) 155(93.9) 144(90.0) 163(92.1) 156(90.7) 0.58 
  Clopidogrel n (%) 132(80.0) 136(85.0) 137(77.4) 147(85.5) 0.15 
  Dual anti-platelet n (%) 126(76.4) 128(80.0) 129(72.9) 136(79.1) 0.40 
  Beta-blocker n (%) 132(80.0) 118(73.8) 136(76.8) 134(77.9) 0.60 
  ACEI/ARB n (%) 128(77.6) 133(83.1) 148(83.6) 144(83.7) 0.39 
  Statin n (%) 159(96.4) 155(96.9) 165(93.2) 163(94.8) 0.38 
Revascularised n (%) 74(44.9) 70(43.8) 70(39.6) 66(38.4) 0.56 
Troponin I (µg/l; median; IQR) 2.5(13.7) 3.2(14.5) 3.5(15.7) 3.1(14.4) 0.90 
FPG (mmol/l; median; IQR) 4.9(0.5) 5.0(0.6) 5.2(0.8) 5.6(1.1) 0.00 
RBG (mmol/l; median; IQR) 5.9(1.93) 6.4(1.75) 6.8(2.4) 7.7(2.8) 0.00 
2HBG (mmol/l; median; IQR) 5.6(1.4) 7.4(0.8) 9.3(1.33) 12.3(3.0) 0.00 
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Table 2. Adverse cardiovascular events in each quartile of 2 hour post load plasma glucose.  
 Q1 n(%) 
(n=165) 
Q2 n(%) 
(n=160) 
 Q3 n(%) 
(n=177) 
Q4 n(%) 
(n=172) 
p  Total n(%) 
(n=674) 
Death 9(5.5) 12(7.5) 23(13.0) 21(12.2) 0.052 65(9.6) 
  Non-cardiovascular 4(2.4) 7(4.4) 9(5.1) 7(4.1) 0.644 27(4.0) 
  Cardiovascular  5(3.0) 5(3.1) 14(7.9) 14(8.1) 0.051 38(5.6) 
Non-fatal MI 13(7.9) 23(14.4) 19(10.7) 32(18.6) 0.021 87(12.9) 
Non-hgic stroke 1(0.61) 0(0.00) 4(2.3) 4(2.3) 0.153 9(1.3) 
MACE 19(11.5) 28(17.5) 37(20.9) 50(29.1) 0.001 134(19.9) 
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Table 3: Adjusted** Risk of adverse events as predicted by APG, FPG and 2h-PG using the Cox 
proportional hazard 
 MACE All cause mortality Cardiovascular mortality Non-fatal MI 
 HR 
95% CI 
P HR 
95% CI 
P HR 
95% CI 
P HR 
95% CI 
P 
2h-PG 
 
1.12 
(1.06-1.19) 
0.00 1.13 
(1.04-1.23) 
0.00 1.19 
(1.08-1.33) 
0.00 1.09 
(1.02-1.17) 
0.01 
FPG 1.28 
(1.07-1.53) 
0.01 1.13 
(0.82-1.54) 
0.46 1.51 
(1.11-2.04) 
0.01 1.15 
(0.90-1.48) 
0.26 
APG 1.03 
(0.95-1.12) 
0.42 1.05 
(0.94-1.16) 
0.42 1.01 
(0.87-1.17) 
0.90 1.03 
(0.93-1.14) 
0.55 
2h-PG 
Quartile* 
1.29 
(1.09-1.53) 
0.00 1.29 
(1.00-1.66) 
0.04 1.44 
(1.03-2.02) 
0.03 1.18 
(0.95-1.45) 
0.13 
* for each higher quartile. **The final model was adjusted for age, gender, history of previous 
myocardial infarction, hypertension and hypercholesterolaemia, discharge diagnosis of STEMI or 
NSTEMI, discharge medication, use of reperfusion therapy and smoking status. 
APG, FPG, 2h-PG are continuous variables  
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Table 4. Candidate predictors affecting end-points for the entire population using Cox proportional-
hazards regression modelling. 
  MACE All cause deaths 
Covariate HR 95% CI  P HR 95% CI  P 
Age 1.03 1.01-1.05 0.0003 1.07 1.04-1.10 0.0001 
2h-PG 1.12 1.04-1.20 0.0012 1.17 1.05-1.30 0.0039 
Previous MI 2.49 1.71-3.62 0.0001 0.98 0.54-1.76 0.9406 
Discharged without beta-blockers 1.60 1.09-2.34 0.0160 1.86 1.08-3.19 0.0241 
Revascularised 1.50 1.05-2.15 0.0273 0.65 0.35-1.21 0.1774 
Hypercholesterolaemia 0.69 0.48-0.99 0.0459 0.79 0.46-1.35 0.3873 
Discharged without clopidogrel 1.51 1.00-2.27 0.0495 2.15 1.25-3.70 0.0055 
Hypertension 1.35 0.94-1.92 0.1007 1.53 0.91-2.56 0.1088 
Discharged without Aspirin 1.29 0.76-2.18 0.3486 1.22 0.58-2.60 0.6012 
Discharge Diagnosis of STEMI 1.18 0.83-1.69 0.3563 1.23 0.72-2.09 0.4426 
Discharged without ACEI/ARB 1.21 0.78-1.86 0.3937 1.78 1.01-3.16 0.0479 
Discharged without Statin 1.27 0.64-2.50 0.4962 1.98 0.90-4.36 0.0904 
Current smoker 0.87 0.56-1.33 0.5062 0.93 0.51-1.68 0.8129 
APG 0.97 0.88-1.06 0.5193 1.01 0.90-1.13 0.9209 
Female gender 0.90 0.60-1.34 0.6030 0.65 0.35-1.19 0.1654 
FPG 1.06 0.84-1.35 0.6186 0.83 0.56-1.22 0.3350 
  
  Cardiovascular Deaths Myocardial infarction 
  HR 95% CI  P HR 95% CI  P 
Age 1.05 1.02-1.09 0.0045 1.02 1.00-1.04 0.0420 
2h-PG 1.17 1.02-1.33 0.0205 1.10 1.01-1.20 0.0291 
Previous MI 1.86 0.91-3.81 0.0911 2.68 1.68-4.23 0.0001 
Discharged without beta-blockers 1.60 0.78-3.27 0.1993 1.71 1.07-2.75 0.0259 
Revascularised 0.82 0.38-1.77 0.6111 1.85 1.19-2.87 0.0064 
Hypercholesterolaemia 0.78 0.39-1.56 0.4808 0.72 0.46-1.12 0.1437 
Discharged without clopidogrel 2.81 1.38-5.72 0.0043 1.08 0.62-1.87 0.7917 
Hypertension 1.30 0.66-2.56 0.4526 1.32 0.85-2.04 0.2204 
Discharged without Aspirin 1.27 0.48-3.38 0.6300 1.45 0.75-2.79 0.2655 
Discharge Diagnosis of STEMI 1.16 0.58-2.30 0.6788 1.23 0.79-1.93 0.3565 
Discharged without ACEI/ARB 2.03 0.99-4.17 0.0541 0.76 0.40-1.42 0.3830 
Discharged without Statin 2.55 0.97-6.67 0.0570 0.83 0.29-2.35 0.7210 
Current smoker 0.72 0.32-1.63 0.4285 1.16 0.68-1.98 0.5789 
APG 0.91 0.78-1.07 0.2644 1.00 0.88-1.12 0.9343 
Female gender 0.80 0.36-1.75 0.5727 0.99 0.61-1.62 0.9782 
FPG 1.25 0.82-1.91 0.2910 0.97 0.71-1.33 0.8332 
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Table 5: Likelihood ratio test comparing nested models containing APG, FPG and 2h-PG individually 
and in combinations. 
 
MODELS MACE All Deaths CVS Death MI CVS Deaths + MI 
1 2 3 χ2 P χ2 P χ2 P χ2 P χ2 P 
FPG FPG 2h-PG  16.01 0.000 7.75 0.005 4.90 0.027 8.64 0.003 15.75 0.000 
FPG APG FPG  0.76 0.383 0.01 0.938 3.62 0.057 0.08 0.780 0.72 0.395 
2h-PG FPG 2h-PG  0.64 0.425 1.52 0.218 1.98 0.159 0.22 0.641 0.13 0.721 
2h-PG APG 2h-PG  1.28 0.258 0.38 0.538 2.80 0.094 0.06 0.806 1.52 0.217 
APG APG FPG  13.82 0.000 0.08 0.783 13.91 0.000 1.16 0.281 10.15 0.001 
APG APG 2h-PG  29.71 0.000 6.68 0.010 16.01 0.000 9.57 0.002 26.58 0.000 
 FPG 2h-PG 
APG 
FPG 
2h-PG 
2.11 0.146 0.10 0.747 4.76 0.029 0.01 0.929 2.01 0.156 
 APG FPG 
APG 
FPG 
2h-PG 
17.36 0.000 7.85 0.005 6.04 0.014 8.57 0.003 17.04 0.000 
 FPG 2h-PG 
APG 
FPG 
2h-PG 
1.47 0.225 1.24 0.265 3.94 0.047 0.17 0.684 0.62 0.432 
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Table 6: Akaike’s Information Criterion for nested and non-nested models for each end point. 
 
Desc of Model AICc δAICc RelLikelihood wi wj/wi 
MACE 
 FPG 605.69 7.69 0.02 0.01 26.18 
 2HPG 598.00 0.00 1.00 0.52 1222.31 
 APG 612.22 14.22 0.00 0.00 1.00 
 FPG 2HPG 599.79 1.79 0.41 0.21 500.22 
 APG FPG 607.42 9.41 0.01 0.00 11.05 
 APG 2HPG 599.47 1.47 0.48 0.25 587.30 
All Cause Deaths 
 FPG 374.14 3.12 0.21 0.09 2.86 
 2HPG 371.02 0.00 1.00 0.42 13.59 
 APG 374.18 3.15 0.21 0.09 2.81 
 FPG 2HPG 372.37 1.35 0.51 0.21 6.93 
 APG FPG 376.24 5.22 0.07 0.03 1.00 
 APG 2HPG 372.94 1.91 0.38 0.16 5.22 
Cardiovascular Deaths 
 FPG 275.00 1.46 0.48 0.15 13.11 
 2HPG 273.54 0.00 1.00 0.31 27.21 
 APG 280.14 6.61 0.04 0.01 1.00 
 FPG 2HPG 274.65 1.11 0.57 0.18 15.58 
 APG FPG 275.29 1.75 0.42 0.13 11.31 
 APG 2HPG 274.24 0.70 0.70 0.22 19.13 
Myocardial Infarction 
 FPG 499.61 4.21 0.12 0.06 2.81 
 2HPG 495.40 0.00 1.00 0.50 23.09 
 APG 500.15 4.76 0.09 0.05 2.14 
 FPG 2HPG 497.39 2.00 0.37 0.19 8.51 
 APG FPG 501.67 6.28 0.04 0.02 1.00 
 APG 2HPG 497.47 2.07 0.35 0.18 8.18 
Cardiovascular Deaths and Myocardial Infarction 
 FPG 586.12 7.81 0.02 0.01 10.57 
 2HPG 578.31 0.00 1.00 0.53 525.05 
 APG 590.84 12.53 0.00 0.00 1.00 
 FPG 2HPG 580.35 2.04 0.36 0.19 189.24 
 APG FPG 587.87 9.55 0.01 0.00 4.42 
 APG 2HPG 579.65 1.34 0.51 0.27 268.28 
AICc=Corrected Akaike’s Information Criterion; δAICc= difference between AICc value for a model 
and minimum AICc i.e. AIC value of the “best” model. wi = Akaike weights, the ratio of δAICc values 
for each model relative to the whole set of candidate models; wj/wi = Evidence ratios, ratio of AICc of 
the “best” model and competing models. All models included age, gender, history of previous 
myocardial infarction, hypertension and hypercholesterolaemia, discharge diagnosis of STEMI or 
NSTEMI, discharge medication, use of reperfusion therapy and smoking status. 
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Table 7: Akaike’s Information Criterion for different non-nested models for each end point. 
Desc of Model AICc DeltaAICc RelLikelihood AkaikeWt EvidenceRatio 
 MACE 
 FPG 605.69 7.69 0.02 0.02 26.18 
 2HPG 598.00 0.00 1.00 0.98 1,222.31 
 APG 612.22 14.22 0.00 0.00 1.00 
All Cause Deaths 
 FPG 374.14 3.12 0.21 0.15 1.02 
 2HPG 371.02 0.00 1.00 0.71 4.84 
 APG 374.18 3.15 0.21 0.15 1.00 
Cardiovascular Deaths 
 FPG 275.00 1.46 0.48 0.32 13.11 
 2HPG 273.54 0.00 1.00 0.66 27.21 
 APG 280.14 6.61 0.04 0.02 1.00 
Myocardial Infarction 
 FPG 499.61 4.21 0.12 0.10 1.31 
 2HPG 495.40 0.00 1.00 0.82 10.78 
 APG 500.15 4.76 0.09 0.08 1.00 
Cardiovascular Deaths and Myocardial Infarction 
 FPG 586.12 7.81 0.02 0.02 10.57 
 2HPG 578.31 0.00 1.00 0.98 525.05 
 APG 590.84 12.53 0.00 0.00 1.00 
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Table 8. Continuous Net Reclassification Improvement for MACE. 
 Add FPG    Add 2h-PG    Add APG    
FPG      E NE TOTAL  E NE TOTAL 
     UP 67 212  UP 83 307  
     DWN 67 328  DWN 51 233  
     TOTAL 134 540  TOTAL 134 540  
     NRI 0 21.481 0.215 NRI 0.239 -0.137 0.102 
     SE   0.097 SE   0.097 
     Z statistic   2.226 Z statistic   1.054 
     p-Value   0.026 p-Value   0.292 
2h-PG  E NE TOTAL      E NE TOTAL 
 UP 66 258      UP 81 312  
 DWN 68 282      DWN 53 228  
 TOTAL 134 540      TOTAL 134 540  
 NRI -1.493 4.444 0.03     NRI 0.209 -0.156 0.053 
 SE   0.097     SE   0.097 
 Z statistic   0.306     Z statistic   0.553 
 p-Value   0.76     p-Value   0.58 
RPG  E NE TOTAL  E NE TOTAL     
 UP 67 199  UP 70 209      
 DWN 67 341  DWN 64 331      
 TOTAL 134 540  TOTAL 134 540      
 NRI 0 26.296 0.263 NRI 4.478 22.593 0.271     
 SE   0.097 SE   0.097     
 Z statistic   2.725 Z statistic   2.805     
 p-Value   0.006 p-Value   0.005     
FPG      E NE TOTAL     
+APG     UP 66 214      
     DWN 68 326      
     TOTAL 134 540      
     NRI -1.493 20.741 0.192     
     SE   0.097     
     Z statistic   1.994     
     p-Value   0.046     
APG  E NE TOTAL         
+2hPG UP 69 256          
 DWN 65 284          
 TOTAL 134 540          
 NRI 2.985 5.185 0.082         
 SE   0.097         
 Z statistic   0.847         
 p-Value   0.397         
FPG          E NE TOTAL 
+2hPG         UP 82 308  
         DWN 52 232  
         TOTAL 134 540  
         NRI 22.388 -14.074 0.083 
         SE   0.097 
         Z statistic   0.861 
         p-Value   0.389 
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Table 9. Categorical Net Reclassification Improvement for MACE. 
 
 Add FPG Add 2h-PG Add APG 
FPG      E NE TOTAL  E NE  
     UP 13 57  UP 4 12  
     DWN 8 84  DWN 2 17  
     TOTAL 134 540  TOTAL 134 540  
     NRI 3.7 5.0 0.087 NRI 1.5 0.9 0.024 
     SE   0.041 SE   0.021 
     Z statistic   2.148 Z statistic   1.161 
     p-Value   0.032 p-Value   0.245 
2h-PG  E NE TOTAL      E NE  
 UP 2 17      UP 3 19  
 DWN 7 10      DWN 5 18  
 TOTAL 134 540      TOTAL 134 540  
 NRI -3.7 -1.3 -0.050     NRI -1.5 -0.2 -0.017 
 SE   0.024     SE   0.024 
 Z statistic   -2.063     Z statistic   -0.701 
 p-Value   0.039     p-Value   0.483 
RPG  E NE TOTAL  E NE TOTAL     
 UP 10 45  UP 20 76      
 DWN 8 64  DWN 13 114      
 TOTAL 134 540  TOTAL 134 540      
 NRI 1.5 3.5 0.050 NRI 5.2 7.0 0.123     
 SE   0.037 SE   0.050     
 Z statistic   1.351 Z statistic   2.457     
 p-Value   0.177 p-Value   0.014     
 
FPG      E NE TOTAL     
+RPG     UP 12 67      
     DWN 9 88      
     TOTAL 134 540      
     NRI 2.2 3.9 0.061     
     SE   0.041     
     Z statistic   1.486     
     p-Value   0.137     
RPG  E NE TOTAL         
+2hPG UP 3 18          
 DWN 1 17          
 TOTAL 134 540          
 NRI 1.5 -0.2 0.013         
 SE   0.019         
 Z statistic   0.706         
 p-Value   0.480         
FPG          E NE TOTAL 
+2hPG         UP 6 20  
         DWN 1 23  
         TOTAL 134 540  
         NRI 3.7 0.6 0.043 
         SE   0.023 
         Z statistic   1.849 
         p-Value   0.064 
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Table 10. Integrated Discrimination Improvement for MACE. 
    Add FPG Add 2h-PG Add APG 
    IDI zIDI P IDI zIDI P IDI zIDI P 
FPG E       0.009     0.000     
  NE       -0.002     0.000     
  TOTAL       0.012 2.175 0.015 0.000 0.126 0.450 
  
2h-PG E 0.001           0.000     
  NE 0.000           0.000     
  TOTAL 0.001 0.847 0.199       0.000 0.105 0.458 
 
RPG E 0.009     0.018           
  NE -0.002     -0.004           
  TOTAL 0.011 2.258 0.012 0.022 3.018 0.001       
  
FPG+RPG E       0.010           
  NE       -0.002           
  TOTAL       0.013 2.192 0.014       
 
RPG+2hPG E 0.001                 
  NE 0.000                 
  TOTAL 0.002 0.941 0.173             
 
FPG+2hPG E             0.001     
  NE             0.000     
  TOTAL             0.001 0.372 0.355 
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Figure legends: 
Figure 1. The distribution of glucometabolic abnormalities according to the NICE 
(CG130) and ESC guidelines. 
Figure 2. Kaplan–Meier curves showing the survival free of major cardiovascular 
adverse events, all cause mortality, cardiovascular mortality and non-fatal 
myocardial infarction in the four quartiles of 2h-PG. 
 
